Non-small-cell lung cancer (NSCLC) comprises the majority of lung cancer about 75-80%, and a quarter of NSCLC cases have mutations in the epidermal growth factor receptor (EGFR) gene. Adenocarcinomas of the lung harboring the L858R mutation in exon 21 have proven to be more adverse in terms of prognosis than exon 19 mutations. Therefore, developing highly sensitive and selective methods to …